MSF calls on G7 leaders to urgently address the critical gaps in global response to public health emergencies and unite to lower the price of live-saving medicines
Exorbitant medicine prices and lack of R&D into needed medicines requires urgent and united action, warns MSF Read more
MSF at the 69th World Health Assembly
Technical Consultation on Preventing and Managing Global Stock Outs of Medicines
Agenda item 16.2: Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination
Agenda Item 14.4: Global Action Plan on Antimicrobial Resistance
Provisional agenda item 15.2 (A69/34) – Global Vaccine Action Plan
Interventions will appear in this space as soon as they have been delivered.
Agenda item 14.4 - Global Action Plan on Antimicrobial Resistance
Agenda item 16.2 - CEWG on R&D Financing and Coordination
Agenda item 16.4 - Addressing the global shortages of medicines, and the safety and accessibility of children’s medication
Agenda item 15.1 - HIV and viral hepatitis, 2016 - 2020
For a schedule of our side events please visit this page.
R&D REPORT: LIVES ON THE EDGE
MSF illustrates how our staff and patients are impacted by the way biomedical R&D is conducted today, and looks at a broad range of policies aimed at changing this dynamic.
READ THE REPORT
TPP: A BAD DEAL FOR MEDICINE
After 5 years of secret negotiations the US and 11 other Pacific countries have reached an agreement on the full text of the TPP which will now be submitted to national processes for final signature and ratification. Read MSF's reaction.
HANDS OFF OUR MEDS
Join us in urging Indian Prime Minister Modi to protect India’s production of lifesaving affordable generic medicines.
TAKE ACTION NOW!
What is the Campaign?
Médecins Sans Frontières set up the Access Campaign in 1999 to push for access to, and the development of life-saving and life prolonging medicines, diagnostic tests and vaccines for patients in MSF programmes and beyond. We are a multi-disciplinary team that includes doctors, pharmacists, scientists, lawyers, as well as advocacy and communications experts. We also work with patient groups and other civil society organisations in response to their concerns over access to treatment.